Cochrane corner: universal screening for SARS-CoV-2 infection
- PMID: 33552376
- PMCID: PMC7846260
- DOI: 10.11604/pamj.supp.2020.37.48.26881
Cochrane corner: universal screening for SARS-CoV-2 infection
Abstract
Introduction: coronavirus disease 2019 (COVID-19) is caused by the novel coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Most people infected with SARS-CoV-2 have mild disease with non-specific symptoms, although a few becoming critically ill with septic shock and multiple organ failure. There is an unknown proportion of infected individuals who remain asymptomatic and infectious. Universal screening for COVID-19 infections to detect individuals who are infected before they present clinically could therefore be an important measure to contain the spread of the disease. We highlight a Cochrane rapid review which assessed the effectiveness and accuracy of universal screening for COVID-19 infection.
Methods: the authors of the Cochrane review searched multiple electronic databases to identify studies reporting on the effectiveness of universal screening and reporting on screening test accuracy. Eligible participants for the review included people who had not sought care for potential COVID-19 symptoms.
Results: the authors included 22 publications, with none of them conducted in Africa. Two modelling studies reported on the beneficial and negative effects of screening; and 20 studies (cohort and modelling) reported data on the accuracy of screening tests. The included studies had wide variability in the baseline prevalence of COVID-19 infection as well as study settings and methods. All cohort studies compared screening strategies to reverse transcriptase-polymerase chain reaction (RT-PCR) as the gold standard. The rapid review suggests that there is low certainty of evidence that screening at travel hubs may slow the importation of infected cases. Furthermore, the review highlights the uncertainty and variation in the accuracy of screening.
Conclusion: given the low accuracy of the tests included in this review, a high proportion of COVID-19 infected individuals may be missed and go on to infect others. In addition, some healthy individuals may be falsely identified as positive, requiring confirmatory testing and potentially leading to the unnecessary isolation of these individuals.
Keywords: COVID-19; SARS-CoV-2; Universal screening; screening test accuracy.
Copyright: Duduzile Ndwandwe et al.
Conflict of interest statement
The authors declare no competing interests.
Similar articles
-
Universal screening for SARS-CoV-2 infection: a rapid review.Cochrane Database Syst Rev. 2020 Sep 15;9(9):CD013718. doi: 10.1002/14651858.CD013718. Cochrane Database Syst Rev. 2020. PMID: 33502003 Free PMC article.
-
Universal COVID-19 screening of 4040 health care workers in a resource-limited setting: an Egyptian pilot model in a university with 12 public hospitals and medical centers.Int J Epidemiol. 2021 Mar 3;50(1):50-61. doi: 10.1093/ije/dyaa173. Int J Epidemiol. 2021. PMID: 33094320 Free PMC article.
-
Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.Trials. 2021 Jan 8;22(1):39. doi: 10.1186/s13063-020-04982-z. Trials. 2021. PMID: 33419461 Free PMC article.
-
Cochrane corner: rapid point-of-care antigen and molecular-based tests for the diagnosis of COVID-19 infection.Pan Afr Med J. 2020 Sep 15;37(Suppl 1):10. doi: 10.11604/pamj.supp.2020.37.10.25982. eCollection 2020. Pan Afr Med J. 2020. PMID: 33294111 Free PMC article.
-
Thoracic imaging tests for the diagnosis of COVID-19.Cochrane Database Syst Rev. 2020 Sep 30;9:CD013639. doi: 10.1002/14651858.CD013639.pub2. Cochrane Database Syst Rev. 2020. Update in: Cochrane Database Syst Rev. 2020 Nov 26;11:CD013639. doi: 10.1002/14651858.CD013639.pub3. PMID: 32997361 Updated.
Cited by
-
A Cost-Benefit Analysis of the COVID-19 Asymptomatic Mass Testing Strategy in the North Metropolitan Area of Barcelona.Int J Environ Res Public Health. 2021 Jun 30;18(13):7028. doi: 10.3390/ijerph18137028. Int J Environ Res Public Health. 2021. PMID: 34209328 Free PMC article.
-
Performance and usefulness of a novel automated immunoassay HISCL SARS-CoV-2 Antigen assay kit for the diagnosis of COVID-19.Sci Rep. 2021 Dec 1;11(1):23196. doi: 10.1038/s41598-021-02636-x. Sci Rep. 2021. PMID: 34853366 Free PMC article.
-
Impact of Mass Workplace COVID-19 Rapid Testing on Health and Healthcare Resource Savings.Int J Environ Res Public Health. 2021 Jul 3;18(13):7129. doi: 10.3390/ijerph18137129. Int J Environ Res Public Health. 2021. PMID: 34281065 Free PMC article.
References
-
- Henderson CE, Rezai S, Jackman JM. Universal screening for novel coronavirus disease 2019 (COVID-19) for asymptomatic parturients: May not be beneficial at this time. J Med Virol. 2020 Sep 11; - PubMed
-
- Herraiz I, Folgueira D, Villalain C, Forcen L, Delgado R, Galindo A. Universal screening for SARS-CoV-2 before labor admission during COVID-19 pandemic in Madrid. J Perinat Med. 2020 Nov 26;48(9):981–984. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous